Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis: A National Cross-Sectional Cohort Study.
Antibodies, Anticardiolipin
/ analysis
Antibodies, Antiphospholipid
Antiphospholipid Syndrome
/ complications
Cohort Studies
Cross-Sectional Studies
Humans
Immunoglobulin G
Immunoglobulin M
Livedo Reticularis
/ diagnosis
Lupus Coagulation Inhibitor
Serbia
/ epidemiology
Thrombocytopenia
Thrombosis
/ diagnosis
beta 2-Glycoprotein I
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
pubmed:
14
6
2022
medline:
4
10
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies (aPLs) associated with thrombosis (arterial and/or venous) and/or obstetrical manifestations. However, various manifestations, which are considered to be noncriteria manifestations, are frequently found in APS. The purpose of this study was to evaluate whether noncriteria manifestations may be found more frequently in subjects with thrombotic and/or obstetrical APS ("criteria" manifestations) in a population of patients with primary APS (PAPS). This study presents the results from our national cohort. This is a cross-sectional study of 360 PAPS patients. Data regarding the presence of thrombocytopenia, livedo reticularis, chorea, and valvulopathy were analyzed. The aPL analysis included the detection of anticardiolipin antibodies (aCLs: immunoglobulin G [IgG]/IgM), anti-β 2 glycoprotein I (IgG/IgM), and lupus anticoagulant positivity. In our cohort, livedo reticularis was significantly related to arterial thromboses in the same way as valvular manifestations (valvular vegetations and valvular thickening and dysfunction not related to age) ( p = 0.0001, p = 0.013, respectively). Age was strongly related to all the noncriteria manifestations analyzed. Thrombocytopenia was significantly related to β 2 glycoprotein I IgG and lupus anticoagulant positivity ( p = 0.043, p = 0.030, respectively), as well as to double and triple aPL positivity ( p = 0.041, p = 0.013 respectively). Moreover, in a multivariate model, livedo reticularis was strongly and independently related to arterial thrombosis in our cohort (odds ratio, 2.010; confidence interval, 1.229-3.288; p = 0.005). This cross-sectional analysis of a large cohort of Serbian PAPS patients confirmed a strong relationship between livedo reticularis and arterial thrombosis, suggesting a more cautious approach regarding the presence of noncriteria manifestations, especially livedo reticularis, in APS.
Sections du résumé
BACKGROUND
BACKGROUND
Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies (aPLs) associated with thrombosis (arterial and/or venous) and/or obstetrical manifestations. However, various manifestations, which are considered to be noncriteria manifestations, are frequently found in APS.
AIM
OBJECTIVE
The purpose of this study was to evaluate whether noncriteria manifestations may be found more frequently in subjects with thrombotic and/or obstetrical APS ("criteria" manifestations) in a population of patients with primary APS (PAPS). This study presents the results from our national cohort.
PATIENTS AND METHODS
METHODS
This is a cross-sectional study of 360 PAPS patients. Data regarding the presence of thrombocytopenia, livedo reticularis, chorea, and valvulopathy were analyzed. The aPL analysis included the detection of anticardiolipin antibodies (aCLs: immunoglobulin G [IgG]/IgM), anti-β 2 glycoprotein I (IgG/IgM), and lupus anticoagulant positivity.
RESULTS
RESULTS
In our cohort, livedo reticularis was significantly related to arterial thromboses in the same way as valvular manifestations (valvular vegetations and valvular thickening and dysfunction not related to age) ( p = 0.0001, p = 0.013, respectively). Age was strongly related to all the noncriteria manifestations analyzed. Thrombocytopenia was significantly related to β 2 glycoprotein I IgG and lupus anticoagulant positivity ( p = 0.043, p = 0.030, respectively), as well as to double and triple aPL positivity ( p = 0.041, p = 0.013 respectively). Moreover, in a multivariate model, livedo reticularis was strongly and independently related to arterial thrombosis in our cohort (odds ratio, 2.010; confidence interval, 1.229-3.288; p = 0.005).
CONCLUSION
CONCLUSIONS
This cross-sectional analysis of a large cohort of Serbian PAPS patients confirmed a strong relationship between livedo reticularis and arterial thrombosis, suggesting a more cautious approach regarding the presence of noncriteria manifestations, especially livedo reticularis, in APS.
Identifiants
pubmed: 35697016
doi: 10.1097/RHU.0000000000001879
pii: 00124743-202210000-00006
doi:
Substances chimiques
Antibodies, Anticardiolipin
0
Antibodies, Antiphospholipid
0
Immunoglobulin G
0
Immunoglobulin M
0
Lupus Coagulation Inhibitor
0
beta 2-Glycoprotein I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
362-366Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet . 2010;376:1498–1509.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost . 2006;4:295–306.
Sciascia S, Amigo MC, Roccatello D, et al. Diagnosing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. Nat Rev Rheumatol . 2017;13:548–560.
Stojanovich L, Djokovic A, Kontic M. Antiphospholipid-mediated thrombosis: interplay between type of antibodies and localisation of lung, and cardiovascular incidences in primary antiphospholipid syndrome. Clin Exp Rheumatol . 2015;33:531–536.
Krause I, Blank M, Fraser A, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology . 2005;210:749–754.
Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis . 2005;64:1490–1493.
Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol . 2005;23:499–504.
Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) . 2013;65:1869–1873.
Radin M, Ugolini-Lopes MR, Sciascia S, et al. Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum . 2018;48:117–120.
Hughes GR. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J . 2003;79:81–83.
Holmqvist M, Simard JF, Asplund K, et al. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open . 2015;1:e000168.
Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev . 2007;6:421–426.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum . 2002;46:1019–1027.
Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev . 2015;14:401–414.
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis . 2019;78:1296–1304.
Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke Criteria for the diagnosis of infective endocarditis. Clin Infect Dis . 2000;30:633–638.
Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus . 2010;19:412–418.
Pengo V, Tripodi A, Reber G, et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost . 2009;7:1737–1740.
Pires da Rosa G, Bettencourt P, Rodríguez-Pintó I, et al. “Non-criteria” antiphospholipid syndrome: a nomenclature proposal. Autoimmun Rev . 2020;19:102689.
Fredi M, Andreoli L, Aggogeri E, et al. Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies. Front Immunol . 2018;9:864.
Guédon AF, Catano J, Ricard L. Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study. Arthritis Res Ther . 2022;24:33.
Radin M, Schreiber K, Cecchi I, et al. The risk of ischaemic stroke in primary APS patients: a prospective study. Eur J Neurol . 2018;25:320–325.
Djokovic A, Stojanovich L, Stanisavljevic N, et al. Relationship between cerebrovascular and valvular manifestations in a Serbian cohort of patients with antiphospholipid syndrome. Clin Exp Rheumatol . 2018;36:850–855.
de Jesús GR, Sciascia S, Andrade D, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and repository: a retrospective study. BJOG . 2019;126:656–661.
Stojanovich L, Kontic M, Djokovic A, et al. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian National Cohort Study. Clin Exp Rheumatol . 2013;31:234–242.
Yelnik CM, Urbanski G, Drumez E, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus . 2017;26:163–169.
Kato M, Hisada R, Atsumi T. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Expert Rev Clin Immunol . 2019;15:73–81.
Udry S, Latino JO, Belizna C, et al. A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunol Res . 2019;67:478–485.